Currently Viewing:
Currently Reading
In Small Amount of Patients, CD4+ T Cells Continue to Decline Despite Being Virally Suppressed
April 18, 2019 – Jaime Rosenberg
Shoshana Lipson Explains How "CGRP & Migraine Community" Supports Patients
April 18, 2019
Is Immunotherapy the Key to Developing an HIV Vaccine?
April 18, 2019 – Wallace Stephens
What We're Reading: Doctors Charged in Opioid Scheme; First US CRISPR Treatment; "Bubble Boy" Disease Cured
April 18, 2019 – AJMC Staff
Dim Light at Night May Help Spread Breast Cancer to Bones
April 18, 2019 – Laura Joszt
Cytomegalovirus May Speed Disease Progression in Cystic Fibrosis
April 17, 2019 – Jaime Rosenberg
Evaluating Revefenacin as a Treatment for COPD
April 17, 2019 – Wallace Stephens
Humana Launches Payment Model to Improve Patient Experience, Outcomes in Cancer Care
April 17, 2019 – Jaime Rosenberg
Bill Seeks to Ban Online Sales of e-Cigarettes, Raise Age to Buy Tobacco to 21
April 17, 2019 – Allison Inserro

EndoPredict Better Than Oncotype DX in Predicting DR in Breast Cancer

Surabhi Dangi-Garimella, PhD
A study has found that an 8-gene signature score, combined with nodal status and tumor size, obtained from the EndoPredict breast cancer test might be more accurate at predicting the recurrence of breast cancer, compared with the recurrence score of Oncotype DX.
A study, funded by Breast Cancer Now, has found that the 8-gene signature (EP score) obtained from the EndoPredict breast cancer test might be more accurate at predicting the recurrence of breast cancer, compared with the recurrence score (RS) of Oncotype DX.

The Oncotype DX Breast Cancer Assay, developed by Genomic Health, is a 21-gene assay that can predict disease recurrence and response to chemotherapy in estrogen receptor (ER)–positive, HER2-negative, early stage breast cancer. EndoPredict (EPclin) combines prognostic information from an 8-gene analysis (EP score) with tumor size and the patient’s nodal status. Both tests have been developed to guide treatment decisions on whether women should receive chemotherapy in addition to anti-hormone treatments. Women who are predicted to be at low risk can be saved the unwanted side effects that are common with chemotherapy treatments.

In the current study, published in the Journal of the National Cancer Institute, scientists from the United Kingdom compared the prognostic information from the RS score and EPclin for a 10-year risk of disease recurrence. The authors compared the RS score, EP score, and the clinicopathologic parameters in 928 patients with ER-positive disease, who had been treated with anastrazole or tamoxifen for 5 years. Both early (0 to 5 years) and late (5 to 10 years) disease recurrence was compared according to the patient’s nodal status.

The analysis showed that EPclin provided significantly more prognostic information that the RS score, especially in patients with nodal disease and who had late disease recurrence. EPclin and RS identified 58.8% and 61.7% patients as low risk, with hazard ratios for non-low versus low risk of 5.99 (95% confidence interval [CI] = 3.94 to 9.11) and 2.73 (95% CI = 1.91 to 3.89), respectively.

Nearly 6% of patients identified as low risk by EPclin developed secondary disease compared with a little over 10% of patients identified as low risk by RS. Importantly, of those classified as low risk by the EndoPredict test, only 0.5% developed secondary breast cancer after a decade, while 7% of those identified as low risk by Oncotype DX had a recurrence.

This study could prove a tremendous advantage to both clinicians and patients, according to the study’s lead author Richard Buus, MD. “It could help improve treatment for a large number of women with breast cancer by allowing doctors to better predict which women are least likely to go on to develop secondary cancer, and could therefore be spared from undergoing the chemotherapy often offered early on in treatment to reduce that risk,” he said in a statement.

“Oncotype DX remains a valuable tool for both clinicians and patients. But we need to see the best and most cost-effective technologies made routinely available on the NHS, and this research suggests EndoPredict could be another step forward. Based on this strong evidence, we would encourage NICE to consider this technology for routine use on the NHS,” Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said.


Buus R, Sestak I, Kronenwett R, et al. Comparison of EndoPredict and EPclin with Oncotype DX recurrence score for prediction of risk of distant recurrence after endocrine therapy. J Natl Cancer Inst. 2016;108(11). pii: djw149. doi:10.1093/jnci/djw149.

Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up